$461 Billion Up for Grabs: Why AI in Healthcare Is Becoming Wall Street’s Sleeper Megatrend July 29, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Momentum behind AI innovation is gaining traction across multiple industries, and now the U.S. government is stepping in to accelerate adoption in healthcare—a sector known for its cautious pace. A new initiative from the Department of Commerce, outlined in President Trump’s recently released Winning the Race: AMERICA’S AI ACTION PLAN, calls for the creation of regulatory sandboxes—controlled testing zones where AI technologies can be trialed with limited regulatory friction but strict oversight. Against this backdrop, a wave of tech and biotech firms are pressing forward with AI-driven healthcare milestones, among them Avant Technologies, Inc. (OTCQB: AVAI), Waystar Holding Corp. (NASDAQ: WAY), CareCloud, Inc. (NASDAQ: CCLD), SoundHound AI, Inc. (NASDAQ: SOUN), and Astrana Health, Inc. (NASDAQ: ASTH). Industry forecasts suggest the payoff could be massive. Accenture estimates that AI could unlock up to $461 billion in added value for healthcare by 2035, pushing the sector past $2.26 trillion. But realizing that potential depends on building systems that deliver reliable results—especially in critical areas like diagnostics and clinical decision-making, where mistakes aren’t just costly, they’re dangerous. Fortunately, several innovators are rising to meet the challenge, developing advanced platforms that aim to transform everything from patient screening to drug discovery. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA’s comments, has now been presented to Fortrea, the company’s contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova’s goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy. “We are committed to meeting the highest regulatory standards, and we’re confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. “We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process.” The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche’s “Macular Spectacular” Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful. Meanwhile, Vision AI has gone live through Grupo Dökka’s Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners. Avant and Ainnova’s FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically. Avant maintains global licensing rights to Ainnova’s platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova’s technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova’s future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer’s, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform. CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Waystar Holding Corp. (NASDAQ: WAY) is acquiring Iodine Software for $1.25 billion to expand its AI-powered clinical intelligence platform. The deal aims to reduce billing errors and improve revenue cycles for healthcare providers using advanced automation. "We are committed to transforming healthcare through harnessing the power of AI to tackle the most critical challenges in healthcare payments," said Matt Hawkins, CEO of Waystar. “Welcoming Iodine's talented team and clinical intelligence platform to Waystar is a terrific next step in achieving our mission." This acquisition strengthens Waystar’s footprint in healthcare AI and positions it to serve 17 of the top 20 U.S. hospitals. CareCloud, Inc. (NASDAQ: CCLD) launched a new AI-driven dermatology EHR designed to streamline practice workflows and improve billing. The cloud-based system features advanced image management and AI-powered charting for faster and more accurate documentation. It's built to help dermatology clinics improve efficiency and deliver better patient care using integrated technology. "Our fully integrated, AI-driven dermatology EHR empowers practices with modern tools that are developed for the unique practice workflows and needs of busy dermatology groups, and designed to enhance their efficiency, accuracy, and financial performance," said Hadi Chaudhry, Co-CEO of CareCloud. "With dermatology services representing a $9 billion segment of the U.S. healthcare market, there’s a clear need for smarter, more efficient technology. By replacing outdated, fragmented systems, with our fully integrated AI-driven system, we are helping dermatologists streamline workflows and focus more on patient care." SoundHound AI, Inc. (NASDAQ: SOUN) partnered with Allina Health to launch 'Alli,' an AI voice agent that automates patient interactions over the phone. "Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance." The system is integrated with Allina’s medical records, helping patients manage appointments and reduce wait times. It improves access to care while freeing up human staff to handle more complex patient needs. Astrana Health, Inc. (NASDAQ: ASTH) completed its $708 million acquisition of Prospect Health, expanding its provider network and value-based care services. The deal brings Astrana access to over 11,000 providers and 600,000 patients across multiple states. "We are excited to welcome Prospect Health's physicians, providers, and team members to Astrana Health," said Brandon Sim, President and CEO of Astrana. "Together, we will further accelerate our mission to drive consistent, coordinated, high-quality patient outcomes at scale, ultimately driving greater value across the healthcare ecosystem." Astrana plans to enhance its AI-enabled care delivery platform to improve outcomes and cut costs at scale. Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
$461 Billion Up for Grabs: Why AI in Healthcare Is Becoming Wall Street’s Sleeper Megatrend July 29, 2025 - Baystreet.ca Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Momentum behind AI innovation is gaining traction across multiple industries, and now the U.S. government is stepping in to accelerate adoption in healthcare—a sector known for its cautious pace. A new initiative from the Department of Commerce, outlined in President Trump’s recently released Winning the Race: AMERICA’S AI ACTION PLAN, calls for the creation of regulatory sandboxes—controlled testing zones where AI technologies can be trialed with limited regulatory friction but strict oversight. Against this backdrop, a wave of tech and biotech firms are pressing forward with AI-driven healthcare milestones, among them Avant Technologies, Inc. (OTCQB: AVAI), Waystar Holding Corp. (NASDAQ: WAY), CareCloud, Inc. (NASDAQ: CCLD), SoundHound AI, Inc. (NASDAQ: SOUN), and Astrana Health, Inc. (NASDAQ: ASTH). Industry forecasts suggest the payoff could be massive. Accenture estimates that AI could unlock up to $461 billion in added value for healthcare by 2035, pushing the sector past $2.26 trillion. But realizing that potential depends on building systems that deliver reliable results—especially in critical areas like diagnostics and clinical decision-making, where mistakes aren’t just costly, they’re dangerous. Fortunately, several innovators are rising to meet the challenge, developing advanced platforms that aim to transform everything from patient screening to drug discovery. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have taken a key regulatory step forward by finalizing an updated clinical trial protocol for their AI-powered Vision AI platform, following formal feedback from a mid-July pre-submission meeting with the FDA. The revised protocol, which addresses the FDA’s comments, has now been presented to Fortrea, the company’s contract research organization, for review. Once approved, the protocol will enable the launch of a new U.S.-based clinical trial designed to support Ainnova’s goal of obtaining FDA 510(k) clearance for Vision AI in the early detection of diabetic retinopathy. “We are committed to meeting the highest regulatory standards, and we’re confident that these protocol refinements will strengthen our path toward FDA 510(k) clearance,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio. “We anticipate finalizing the clinical trial budget soon, with estimated costs coming more into focus as we refine our protocol and navigate the process.” The U.S. regulatory push builds on expanding visibility for Vision AI across Latin America. In June, Vargas was featured at Roche’s “Macular Spectacular” Ophthalmology Conference in Cartagena, Colombia, where he presented Vision AI as a cost-effective screening tool that can prevent diabetic blindness and improve health access in low-resource settings. He also highlighted a Q4 2024 pilot with Roche and Salud 360 that could scale across the U.S., Canada, and Europe if successful. Meanwhile, Vision AI has gone live through Grupo Dökka’s Fischel and La Bomba pharmacy chains, offering walk-in screenings, real-time AI results, and direct referrals to care providers. The model eliminates the need for onsite ophthalmologists and is gaining traction with pharmacy chains, insurers, and life sciences partners. Avant and Ainnova’s FDA engagement follows an earlier pre-submission meeting in July, where the agency provided clear guidance on study design and compliance. The refined clinical trial protocol, once greenlit, will guide a formal U.S. study aimed at supporting FDA clearance to market Vision AI domestically. Avant maintains global licensing rights to Ainnova’s platform through Ai-nova Acquisition Corp., the JV established to commercialize Ainnova’s technology portfolio. U.S. entry is viewed as a major inflection point with significant commercial potential. Looking ahead, Vision AI could serve as a frontline tool for broader disease detection. Ainnova’s future roadmap includes a cloud-connected retinal camera for rural clinics and new modules aimed at identifying Alzheimer’s, cardiovascular conditions, and other chronic diseases through retinal or blood biomarkers. Avant has also signaled plans for a dedicated therapeutic-focused spinout and continues to evaluate a full acquisition of Ainnova Tech under a previously announced non-binding LOI—potentially consolidating all assets and leadership under a single public platform. CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ Waystar Holding Corp. (NASDAQ: WAY) is acquiring Iodine Software for $1.25 billion to expand its AI-powered clinical intelligence platform. The deal aims to reduce billing errors and improve revenue cycles for healthcare providers using advanced automation. "We are committed to transforming healthcare through harnessing the power of AI to tackle the most critical challenges in healthcare payments," said Matt Hawkins, CEO of Waystar. “Welcoming Iodine's talented team and clinical intelligence platform to Waystar is a terrific next step in achieving our mission." This acquisition strengthens Waystar’s footprint in healthcare AI and positions it to serve 17 of the top 20 U.S. hospitals. CareCloud, Inc. (NASDAQ: CCLD) launched a new AI-driven dermatology EHR designed to streamline practice workflows and improve billing. The cloud-based system features advanced image management and AI-powered charting for faster and more accurate documentation. It's built to help dermatology clinics improve efficiency and deliver better patient care using integrated technology. "Our fully integrated, AI-driven dermatology EHR empowers practices with modern tools that are developed for the unique practice workflows and needs of busy dermatology groups, and designed to enhance their efficiency, accuracy, and financial performance," said Hadi Chaudhry, Co-CEO of CareCloud. "With dermatology services representing a $9 billion segment of the U.S. healthcare market, there’s a clear need for smarter, more efficient technology. By replacing outdated, fragmented systems, with our fully integrated AI-driven system, we are helping dermatologists streamline workflows and focus more on patient care." SoundHound AI, Inc. (NASDAQ: SOUN) partnered with Allina Health to launch 'Alli,' an AI voice agent that automates patient interactions over the phone. "Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance." The system is integrated with Allina’s medical records, helping patients manage appointments and reduce wait times. It improves access to care while freeing up human staff to handle more complex patient needs. Astrana Health, Inc. (NASDAQ: ASTH) completed its $708 million acquisition of Prospect Health, expanding its provider network and value-based care services. The deal brings Astrana access to over 11,000 providers and 600,000 patients across multiple states. "We are excited to welcome Prospect Health's physicians, providers, and team members to Astrana Health," said Brandon Sim, President and CEO of Astrana. "Together, we will further accelerate our mission to drive consistent, coordinated, high-quality patient outcomes at scale, ultimately driving greater value across the healthcare ecosystem." Astrana plans to enhance its AI-enabled care delivery platform to improve outcomes and cut costs at scale. Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.